The Unmet Need: Why Complement Inhibition Is Not Enough

Geographic atrophy (GA) is an advanced, irreversible form of age-related macular degeneration affecting an estimated one million patients in the United States and five million globally. The condition is defined by progressive loss of retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris in the macular region — a convergent degenerative cascade that complement inhibitors, despite their recent regulatory approvals, do not fully arrest. Academic literature retrieved across this patent analysis explicitly notes that “there are currently no approved treatments to slow photoreceptor and retinal pigment epithelium degeneration” beyond complement inhibitors, framing the broader non-complement pipeline as an area of active, urgent inquiry.

The failure of lampalizumab — an anti-complement Factor D antibody — to reduce GA expansion versus sham in a 906-participant Phase III trial at 48 weeks is a defining reference point for the field. That result, cited as background context across multiple filings in this dataset, has accelerated interest in mechanisms that operate entirely outside the complement cascade: mitochondrial neuroprotection, trophic factor replacement, lipid clearance, RPE cell transplantation, gap junction modulation, and physical energy delivery.

The structural targets that matter most are RPE and photoreceptor integrity — both measurable via optical coherence tomography (OCT) and fundus autofluorescence (FAF) imaging. Apellis Pharmaceuticals’ filings introduce photoreceptor (PR) integrity loss and RPE loss as quantifiable lesion sub-phenotypes, derived from the OAKS and DERBY clinical trials, providing a clinical measurement framework applicable to any neuroprotective or cell-replacement strategy seeking patient selection biomarkers. Mitochondrial dysfunction in RPE and photoreceptors, reduced PEDF expression, dysregulated gap junction signalling, and drusen lipid accumulation are among the co-pathogenic mechanisms that complement inhibition leaves unaddressed — and that the emerging pipeline directly targets.

Neuroprotective Approaches: Mitochondria, Trophic Factors, and Small Molecules

The most mechanistically substantiated non-complement neuroprotective approaches in this patent dataset target three distinct cellular vulnerabilities: mitochondrial bioenergetic failure in photoreceptors and RPE, loss of endogenous trophic support via PEDF, and drusen-driven lipid accumulation that accelerates RPE stress. Each has active commercial IP, though most remain at preclinical to early translational stages.

Elamipretide: Organelle-Level Intervention

Elamipretide (SS-31) is a mitochondria-targeted cardiolipin-binding tetrapeptide developed by Stealth Biotherapeutics Inc. Two patent filings — one in the WO jurisdiction (2024) and one in the AU jurisdiction (2025) — claim methods for using elamipretide to treat or slow progression of photoreceptor loss, GA secondary to AMD, and non-exudative dry AMD. The mechanism involves stabilisation of mitochondrial inner membrane cardiolipin, reduction of reactive oxygen species, and preservation of mitochondrial membrane potential in the energy-demanding photoreceptor and RPE cells. The filings cite preclinical literature including Huang et al. (Curr Mol Med 2013) on SS-31 retinal protection in diabetic rats as mechanistic support, and reference published clinical data (Jaffe GJ, Chakravarthy U, Freund KB et al.) in the bibliography, suggesting IND-enabling and early clinical-stage activity.

PEDF: Trophic Factor Replacement for Choriocapillaris Protection

Pigment epithelium-derived factor (PEDF), the protein product of the SERPINF1 gene, is represented across four CureBiotec GmbH patent filings spanning JP and CN jurisdictions. PEDF is an endogenous survival and anti-angiogenic factor whose reduced expression contributes to choriocapillaris loss, GA formation, and progression. CureBiotec’s filings claim that PEDF inhibits GA growth and formation in both wet and dry AMD, induces non-leaking choriocapillaris growth, protects existing choriocapillaris, and inhibits extracellular matrix formation. A mechanistically differentiated claim across these filings is the co-administration of PEDF with VEGF — the rationale being that VEGF at sub-pathological levels supports choriocapillaris survival while PEDF suppresses aberrant neovascularisation and fibrosis. A 2025 JP filing explicitly targets patients with GA risk on concurrent anti-VEGF therapy, addressing the known complication of GA in long-term anti-VEGF-treated patients.

“The co-administration of PEDF with VEGF challenges the dominant anti-VEGF paradigm — simultaneously protecting physiological choriocapillaris while suppressing the aberrant vessels that anti-VEGF monotherapy targets.”

Apolipoprotein Mimetics and High-Dose Statins: Lipid Clearance as Neuroprotection

MacRegen, Inc. holds JP patents covering apolipoprotein mimetics — synthetic peptides mimicking the lipid-clearing activity of apoA-I and apoE — for all stages and phenotypes of AMD, including central and non-central GA. The therapeutic rationale spans drusen lipid clearance, oxidative stress reduction, anti-inflammatory activity, and anti-neovascularisation. MacRegen explicitly positions apo mimetics as combinable with complement inhibitors and anti-angiogenic agents, signalling a multi-pathway combination strategy.

Massachusetts Eye and Ear Infirmary holds multiple active JP patents (2022, 2025) covering high-dose statins for AMD, with claims including drusen regression, drusenoid pigment epithelial detachment regression, prevention of RPE atrophy, prevention of photoreceptor atrophy, and prevention of progression from dry to wet AMD. The neuroprotective rationale operates through lipid clearance and the pleiotropic anti-inflammatory effects of statins at doses exceeding standard cardiovascular dosing. The filings contain clinical context referencing patient outcomes, suggesting translational activity. Both the MacRegen and Massachusetts Eye and Ear Infirmary approaches are supported by research from institutions tracked by NIH-funded macular degeneration programmes.

Novel Small Molecule Scaffolds

Two additional small molecule programmes appear in this dataset. Ocuphire Pharma, Inc. filed a WO patent (2025, priority to a 2023 US provisional) covering substituted 2,3-dimethoxyquinones for treating GA — a quinone scaffold associated with mitochondrial electron transport chain support and antioxidant activity, addressing RPE bioenergetic failure. Orion Ophthalmology LLC filed a patent (PH jurisdiction, 2024) covering heterocyclic prolinamide derivatives for prevention and treatment of dry AMD, wet AMD, and GA, as well as diabetic retinopathy, with an implied neuroprotective mechanism against photoreceptor and retinal cell degeneration. Both are at early patent prosecution stage.

Cell Therapy and Vascular Restoration Strategies

Cell therapy for geographic atrophy targets the irreversible structural deficit that pharmacological neuroprotection cannot reverse: the loss of the RPE monolayer itself. Lineage Cell Therapeutics, Inc. holds a CN patent filing (2024) covering methods, compositions, and devices for treating eye diseases and conditions including macular degeneration and GA. The filing includes explicit, quantitative claims about reducing GA growth relative to control — specifically, growth less than approximately 65%, 60%, 50%, 40%, 30%, 20%, or 10% of control — language typically derived from clinical trial protocols or interim data, signalling translational progression consistent with the company’s OpRegen RPE cell transplant programme.

The University of California (Regents) holds a JP patent filing (2024) addressing non-leaking or minimally leaking choroidal and retinal revascularisation using pro-angiogenic and vascular maturation factors — a mechanistic complement to cell replacement strategies targeting choriocapillaris restoration. This approach, referenced alongside Lineage’s cell therapy IP, points toward a future in which RPE transplantation and vascular bed restoration are combined rather than pursued independently. According to research frameworks established by NIH and the National Eye Institute, restoring both the RPE monolayer and its underlying vascular support is increasingly viewed as a prerequisite for durable visual recovery in GA.

Two additional, mechanistically distinct modalities appear in this section of the dataset. Allergan, Inc. holds a JP patent (2020, now inactive) covering brimonidine — an alpha-2 adrenergic receptor agonist with established neuroprotective properties in the retinal ganglion cell context — for treating or slowing GA lesion growth, including clinical trial design methods. Brimonidine was evaluated in a sustained-release intravitreal implant format (Allergan’s Brimo DDS). The patent is inactive, suggesting the programme did not advance, but it provides a historical clinical precedent for non-complement small-molecule GA trials and establishes GA lesion growth rate as an acceptable primary endpoint.

Gary E. Borodic holds multiple active IL (Israel) patents (2019, 2024) for botulinum neurotoxin-based formulations applied to an extra-ocular region with axoplasmic transport into the choroid, neuroretina, and RPE for AMD treatment. The claimed safety advantage is elimination of direct intraocular injection risk while allowing active ingredient penetration to target retinal layers. The hypothesised mechanism involves modulation of sympathetic innervation of choroidal vasculature, with potential neuroprotective secondary effects. Breyer Therapies Ltd. holds a CN patent filing (2024) covering gap junction-dependent cell modulators for treating dry AMD and preventing progression to GA or wet AMD, centring on connexin-mediated RPE cell-to-cell communication as a target for maintaining RPE sheet integrity.

Combination Strategies and the Precision Medicine Turn

Combination strategies pairing complement modulation with neuroprotection or trophic factors are increasingly signalled across this patent dataset, suggesting that single-mechanism GA therapies may face competitive pressure from co-targeting agents. The Innovent Biologics (Suzhou) Co., Ltd. filings cover bispecific fusion proteins inhibiting both the complement pathway and the VEGF pathway for AMD treatment, with claims on delaying GA onset in wet AMD patients. Gyroscope Therapeutics’ gene therapy filings take a similar dual-pathway approach via AAV-delivered aflibercept combined with complement Factor I (CFI) and Complement Factor H-like protein 1 (FHL1) — a gene therapy approach to complement modulation with direct GA relevance.

MacRegen’s apolipoprotein mimetic filings explicitly position apo mimetic peptides as usable in combination with complement inhibitors and anti-angiogenic agents, signalling a multi-modality combinatorial strategy. CureBiotec’s PEDF + VEGF co-delivery approach is the most mechanistically novel combination in this dataset — simultaneously administering PEDF to protect choriocapillaris and suppress aberrant vessels, while providing VEGF at sub-pathological levels to support physiological choriocapillaris survival. This directly challenges the dominant anti-VEGF paradigm for GA-at-risk patients receiving long-term intravitreal anti-VEGF therapy, and a 2025 JP filing explicitly targets this patient population.

The precision medicine trajectory is reinforced by Apellis Pharmaceuticals’ introduction of photoreceptor (PR) layer integrity loss and RPE loss as quantifiable lesion sub-phenotypes from the OAKS and DERBY trials. This OCT-based patient stratification framework — PR-RPE quartile stratification — has direct relevance for any neuroprotective or cell-replacement strategy seeking to enrich trial populations for treatment response. According to imaging standards tracked by the FDA and international bodies including the EMA, validated imaging biomarkers are increasingly accepted as surrogate endpoints in GA clinical trials, lowering the evidentiary bar for early-stage neuroprotective programmes with robust imaging data.

Photobiomodulation: A Conspicuous White Space in the GA Patent Landscape

Photobiomodulation (PBM) for geographic atrophy is absent from this dataset as a GA-specific approach. No GA-specific photobiomodulation patents or papers were recovered across the targeted searches that produced this analysis. The only retrieved PBM patent — from Keimyung University (Korea, 2021) — covers PBM to induce brain-derived neurotrophic factor (BDNF) expression in hippocampal tissue for brain diseases including depression and dementia, and does not claim ocular or retinal applications. While BDNF has theoretical relevance to retinal neuroprotection given its role in supporting retinal ganglion cell survival — a mechanism documented in research published by Nature and related neuroscience journals — the absence of GA-specific PBM IP in this dataset is itself a strategic signal.

This absence represents either a genuine white-space IP opportunity or a signal of pre-commercial stage activity that has not yet reached patent prosecution. Developers with PBM platforms validated in other retinal or neurological indications should evaluate whether retinal GA constitutes a defensible extension claim — particularly given that the GA field lacks any approved physical-energy-delivery modality and that PBM has established safety profiles in adjacent ophthalmic applications. The WIPO patent database and related national patent offices would be the appropriate venues for a comprehensive freedom-to-operate analysis before entering this space.

Strategic Implications for Drug Developers and IP Strategists

The geographic atrophy non-complement patent landscape, as represented in this dataset, reveals a field in active mechanistic diversification — with implications for freedom-to-operate analysis, clinical trial design, and licensing strategy across multiple stakeholder categories.

Freedom-to-Operate Priorities

Mitochondrial neuroprotection (elamipretide) and PEDF-based trophic factor replacement represent the two mechanistically best-supported non-complement, non-cell-therapy approaches in this dataset. Each has active commercial IP and mechanistic rationale anchored in RPE and photoreceptor biology. Developers evaluating these spaces should assess freedom-to-operate relative to Stealth Biotherapeutics (WO and AU filings, 2024–2025) and CureBiotec GmbH (JP and CN filings, 2022–2025) respectively before advancing candidates with overlapping mechanisms or formulation strategies.

Cell Therapy IP Monitoring

Cell therapy IP from Lineage Cell Therapeutics includes specific, quantitative GA growth-reduction claims that will require robust clinical data to support. IP strategists should monitor CN and WO continuation filings as clinical data matures, as these claims define a commercially significant efficacy benchmark for the RPE transplant space. The quantitative framing — GA growth less than 65%, 60%, 50%, 40%, 30%, 20%, or 10% of control — establishes a graduated claims ladder that will shape licensing negotiations and competitive positioning as the OpRegen programme advances.

Imaging AI as Essential Trial Infrastructure

Deep learning-based GA progression prediction tools from Genentech (WO, US filings) and Novartis (EP, US filings) are becoming essential infrastructure for clinical development of any GA therapeutic. Academic and biotech developers lacking proprietary imaging AI should consider licensing or partnership pathways with these platform holders to enable precision patient enrichment in non-complement GA trials. The Apellis OAKS and DERBY trial data — introducing PR-RPE quartile stratification — provides a publicly available clinical framework that developers can reference for trial design even without proprietary imaging AI.

“Single-mechanism GA therapies may face competitive pressure from co-targeting agents — the Innovent Biologics bispecific fusion protein and Gyroscope Therapeutics gene therapy dual-payload approaches signal that combination strategies are a near-term development priority.”

Combination Strategy and Licensing

Combination strategies pairing complement modulation with neuroprotection or trophic factors are increasingly signalled in this dataset. The Innovent Biologics bispecific fusion protein and Gyroscope Therapeutics gene therapy dual-payload approaches suggest that single-mechanism GA therapies may face competitive pressure from co-targeting agents. This has direct implications for both clinical trial design — where combination arms may be required to demonstrate superiority — and for licensing strategy, where neuroprotective or trophic factor assets may command greater value as combination partners than as standalone programmes.